How to appeal a Cigna ms treatments denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for ms treatments

Cited policy: Cigna Drug coverage policy - Ocrevus / ocrelizumab; Multiple Sclerosis Agents PA criteria

Neurologist-confirmed MS per McDonald criteria. Step therapy through preferred DMT(s) - varies by plan. Documented disease activity within preceding 12 months for high-efficacy. Tysabri: TOUCH + JCV index documented.

How Cigna denies ms treatments — and how to counter it

Where Cigna pushes back: 1) Trial Tecfidera or Aubagio before Ocrevus/Kesimpta; 2) Lack of recent MRI showing activity; 3) Continuation request without re-documenting ongoing benefit; 4) Rituximab off-label denied as 'not FDA-approved for MS'.

Counter-arguments that hold up: AAN 2018 escalation logic supports moving directly to high-efficacy DMT after demonstrated breakthrough — recognized standard of care. ASCLEPIOS I/II showed Kesimpta superior to Aubagio — requiring an already-proven-inferior agent first is clinically inappropriate. For rituximab: Hauser 2008 NEJM (HERMES), Granqvist 2018 JAMA Neurol (superior persistence), Salzer 2016 Swedish registry safety. FDA off-label ≠ lack of medical necessity (AMA + case law). Ocrelizumab is the FDA-approved congener with shared mechanism if cost is barrier.

What Cigna typically denies for ms treatments

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For ms treatments, expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the ms treatments treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Ocrevus
• Kesimpta
• Briumvi
• Tysabri
• Lemtrada
• S1P modulator

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.